Tirzepatide vs Retatrutide
A side-by-side comparison of Tirzepatide and Retatrutide, including efficacy data, side effects, dosing, and cost.
Feature
Tirzepatide
Retatrutide
Drug Class
GLP-1 and GIP dual receptor agonist
GLP-1, GIP, and glucagon triple receptor agonist
Brand Names
Mounjaro, Zepbound
None yet
Form
Once-weekly injection
Once-weekly injection (investigational)
Dosing
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (weekly)
1 mg → 2 mg → 4 mg → 8 mg → 12 mg (weekly, clinical trial dosing)
FDA Approval
Type 2 diabetes (Mounjaro); Chronic weight management (Zepbound)
Not yet FDA approved (Phase 3 trials ongoing)
Efficacy
Average 20-22% body weight loss over 72 weeks (SURMOUNT trials)
Average 24% body weight loss over 48 weeks (Phase 2 trials)
Cost
$1,000-$1,500/month without insurance
Not yet available commercially
Tirzepatide Side Effects
- •Nausea
- •Diarrhea
- •Decreased appetite
- •Vomiting
- •Constipation
- •Indigestion
Retatrutide Side Effects
- •Nausea
- •Diarrhea
- •Increased heart rate
- •Vomiting
- •Constipation
Which one should you choose?
The best medication depends on your health goals, insurance coverage, and how your body responds. Tirzepatide is a glp-1 and gip dual receptor agonist, while Retatrutide is a glp-1, gip, and glucagon triple receptor agonist, which can affect both efficacy and side effects.
Always consult your healthcare provider before starting or switching medications.